The study analyzed treatment outcomes for hepatocellular carcinoma (HCC) related to newly established oncological resectability criteria. Results showed median survival times were 107.2 months for resectable (R) patients, 44.4 months for BR1, and only 18.4 months for BR2 patients. The data indicate that these criteria effectively stratify prognosis post-hepatectomy, with poor outcomes for BR2 patients […]

The 2024 IHPBA Legacy Initiative targets hepatocellular carcinoma (HCC) in sub-Saharan Africa, addressing significant healthcare challenges due to high incidence rates and inadequate infrastructure. It focuses on enhancing management pathways and access to care through a multidisciplinary approach, including prevention, early diagnosis, and treatment strategies. Key efforts involve expanding healthcare resources, implementing screening programs, and […]

In a systematic review of eight studies involving 6,648 patients, robotic pancreaticoduodenectomy (RPD) demonstrated significant advantages over laparoscopic pancreaticoduodenectomy (LPD) for malignant lesions. Key findings included a reduced length of hospitalization (mean difference of -0.94 days), lower conversion rates (odds ratio of 0.20), and a higher number of harvested lymph nodes (mean difference of 1.02). […]

Single-cell analyses reveal significant insights into lymph node metastasis in intrahepatic cholangiocarcinoma (ICCA). A complex heterogeneity was identified within the lymph node microenvironment, with an increase in stromal and mature immune cells, particularly diverse T cell subtypes. Notably, CD36+ macrophages and SAA1+ tumor cells were implicated as critical components in the metastatic process. These findings […]

A new predictive model significantly enhances the accuracy of forecasting 5-year recurrence rates in hepatocellular carcinoma (HCC) patients post-surgery. Integrating LASSO regression and random forest techniques, the model identified six key factors, achieving an area under the curve (AUC) of 0.733, compared to the initial model’s AUC of 0.678. Importantly, this model demonstrates better predictive […]

A 65-year-old man with unresectable, microsatellite-high intrahepatic cholangiocarcinoma experienced significant tumor shrinkage after receiving pembrolizumab, following a failed combination therapy. The comprehensive cancer genomic profiling identified an mlh1 pathogenic mutation, suggesting the microsatellite instability was somatic rather than inherited. Remarkably, the response was maintained for over 30 months, indicating pembrolizumab’s potential effectiveness in treating this […]

In high-risk advanced hepatocellular carcinoma patients, triple therapy involving FOLFOX-based hepatic arterial infusion, tyrosine kinase inhibitors, and PD-1 inhibitors significantly improved median overall survival to 24.6 months compared to 11.9 months with dual therapy (HR=0.43, p

A novel predictive model using lasso-logistic regression has been developed to assess the risk of postpancreatectomy hemorrhage. Analyzing data from over 9,600 patients, the model identifies nine independent risk factors, including preoperative BMI and ASA scores. Its predictive accuracy reached an area under the ROC curve of 0.87 during external validation, outperforming previous models significantly. […]